# Azacitidine and CAPOX in Metastatic Colorectal Cancer

> **NCT01193517** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Azacitidine MTD

## Key facts

- **NCT ID:** NCT01193517
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193517, "Azacitidine and CAPOX in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01193517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*